Zack Mager
Vice President·OrbiMed
Bio
Professional summary
Zack Mager is a Vice President on OrbiMed's Investor Services team, which he joined in 2023. Before OrbiMed, he worked as a Senior Associate on the Investor Services team at Centerbridge Partners and was previously an Associate at Morgan Stanley. He earned a B.A. from SUNY Oneonta.
Background
Career, education, and skills
Career history
- OrbiMedVice President, Investor Services2023 – Present
- Centerbridge PartnersSenior Associate, Investor Services
- Morgan StanleyAssociate
Education
- SUNY OneontaB.A.
Other partners at OrbiMed
12 more profiles
Aditya Tolia
Private Equity Senior Analyst
OrbiMed
Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.
Alexis Megibow
Private Equity Associate
OrbiMed
Private Equity Associate at OrbiMed.
Ankesh Bhansali
Managing Director
OrbiMed
OrbiMed Asia Managing Director focused on healthcare private equity.
Arun Sadhanandham
Managing Director
OrbiMed
OrbiMed Asia Managing Director investing in healthcare private equity.
Brendan Weber, CFA
Principal
OrbiMed
Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.
Carl Gordon
Managing Partner
OrbiMed
OrbiMed Managing Partner leading private equity and biotech company formation.
Carl L. Gordon
Managing Partner
OrbiMed
Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.
Carter Neild
Managing Partner
OrbiMed
OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.
Clay Daniel DeMarcus
Principal
OrbiMed
Principal focused on medical technology and non-therapeutics venture investing.
Cooper Steputis
Private Equity / Venture Capital
OrbiMed
Healthcare private equity and venture investor with prior investment banking experience.
Daniel Ying
Executive Director
OrbiMed
OrbiMed Asia Executive Director focused on pharma and biotech investments.
David Bonita
General Partner
OrbiMed
OrbiMed General Partner and physician-investor in healthcare and therapeutics.